Oscar Health, Inc. (NYSE:OSCR – Get Free Report) CEO Mark Bertolini sold 615,142 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $28.61, for a total transaction of $17,599,212.62. Following the completion of the transaction, the chief executive officer owned 9,581,734 shares of the company’s stock, valued at approximately $274,133,409.74. This represents a 6.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Oscar Health Trading Down 3.1%
Shares of Oscar Health stock opened at $28.54 on Wednesday. The firm has a 50-day simple moving average of $23.56 and a two-hundred day simple moving average of $17.55. The company has a market cap of $8.61 billion, a P/E ratio of -48.38, a price-to-earnings-growth ratio of 2.06 and a beta of 2.37. Oscar Health, Inc. has a fifty-two week low of $10.69 and a fifty-two week high of $30.66. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.11 and a current ratio of 1.11.
Oscar Health (NYSE:OSCR – Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.96. Oscar Health had a negative net margin of 0.30% and a negative return on equity of 3.26%. The business had revenue of $4.65 billion for the quarter, compared to analyst estimates of $4.90 billion. During the same period in the prior year, the company posted $0.92 EPS. The company’s revenue for the quarter was up 52.6% on a year-over-year basis. As a group, equities analysts predict that Oscar Health, Inc. will post 0.47 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Oscar Health
Analyst Ratings Changes
A number of analysts have recently commented on the company. Wells Fargo & Company set a $20.00 price objective on Oscar Health and gave the company an “equal weight” rating in a research report on Thursday, June 4th. Robert W. Baird increased their target price on Oscar Health from $15.00 to $19.00 and gave the company a “neutral” rating in a research report on Thursday, May 7th. UBS Group lifted their price target on shares of Oscar Health from $15.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Zacks Research lowered shares of Oscar Health from a “strong-buy” rating to a “hold” rating in a report on Friday, June 5th. Finally, Wolfe Research began coverage on shares of Oscar Health in a research report on Tuesday, May 5th. They set a “peer perform” rating for the company. Three research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Oscar Health presently has a consensus rating of “Hold” and a consensus target price of $20.78.
View Our Latest Analysis on Oscar Health
About Oscar Health
Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.
The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.
Featured Stories
- Five stocks we like better than Oscar Health
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Oscar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oscar Health and related companies with MarketBeat.com's FREE daily email newsletter.
